Clinical trial
Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation
NCT00209222 is registered in ClinicalTrials.gov with European Mantle Cell Lymphoma Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation
- Lead sponsor
- European Mantle Cell Lymphoma Network
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- July 31, 2004
- Completion date
- December 31, 2014
- Enrollment
- 360 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.